Safety and Durability of Sirolimus for Treatment of LAM
Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The MIDAS study aims to follow LAM patients who are currently taking, have previously failed
or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or
everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with
or without lung cysts.
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati University of Cincinnati
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH) Rare Diseases Clinical Research Network The LAM Foundation